Yet another biotech with promising cancer therapies but struggled with clinical and regulatory operations. Telomerase-based cancer therapy has potential for broad applicability unlike targeted therapies, so their “platform” potential is why Geron attracted so much attention and funding despite execution setbacks.
Yet another biotech with promising cancer therapies but struggled with clinical and regulatory operations. Telomerase-based cancer therapy has potential for broad applicability unlike targeted therapies, so their “platform” potential is why Geron attracted so much attention and funding despite execution setbacks.